NCT02106091终止1 期
A Pharmacodynamically-guided, Dose-escalation, Phase I Study to Assess the Safety of AFM11 (Recombinant Antibody Construct Against Human CD19 and CD3) in Patients With Relapsed and/or Refractory CD19 Positive B-cell NHL.
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 终止
- 发起方
- Affimed GmbH
- 入组人数
- 16
- 试验地点
- 7
- 主要终点
- Number of participants with serious and non-serious adverse events as a measure of safety and tolerability of AFM11.
研究概览
简要总结
The purpose of this study is to determine whether AFM11 is safe and active in the treatment of relapsed and/or refractory Non-Hodgkin Lymphoma (NHL).
详细描述
CD19 is present on B-cells from earliest recognizable B-lineage cells during development to B-cell blasts and is lost only upon maturation to plasma cells. Expression of CD19 on B-cells at various development stages makes it an ideal target to treat B-cell associated malignancies.The rationale for the use of AFM11 is based on its ability to bind to both malignant cells via its anti-CD19 domain and to T-cells via its anti-CD3 domains. This results in the formation of the "immunological synapse" and the subsequent T-cell activation on leading to killing of malignant cells.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients with CD19+, relapsed or refractory histologically (WHO classification) confirmed follicular lymphoma, marginal zone lymphoma, lymphoplasmocytic lymphoma, mantle cell lymphoma, diffuse large B-cell lymphoma, mediastinal B-cell lymphoma, or transformed B-cell lymphomas.
- •Patients with either indolent or aggressive NHL.
- •Patients who relapsed or were refractory to the approved standard therapy, which must have included 1 treatment line with rituximab plus chemotherapy, and who are not candidates for bone marrow transplant (including both peripheral blood and hematopoietic stem cell transplants with a curative intent.
- •Measurable disease (at least 1 lesion ≥ 1.5 cm) documented by CT scan.
- •Disease progression requiring therapy.
- •Eastern Cooperative Oncology Group (ECOG) performance status ≤
- •Life expectancy of at least 6 months.
- •Ability to understand the patient information and informed consent form.
- •Signed and written informed consent
排除标准
- •Total number of B-cells (healthy and malignant combined) in the peripheral blood exceeds the upper physiological limit (as per institutional guidance) of total B-cell counts in healthy individuals.
- •Autologous Hematopoietic stem cell transplant (HSCT) within 12 weeks prior to start of AFM11 treatment.
- •Abnormal hematological laboratory values as defined below:
- •Peripheral lymphocyte count > 20 × 10^9/L
- •Platelet count ≤ 75,000/µL
- •Hemoglobin level ≤ 9 g/dL.
- •Known or suspected central nervous system (CNS) involvement.
- •History of or current relevant CNS pathology as epilepsy, seizure, paresis, aphasia, apoplexia, severe brain injuries, cerebellar disease, organic brain syndrome, and/or psychosis.
- •Evidence for presence of malignant disease, inflammatory lesions, and/or vasculitis on cerebral MRI.
- •Infiltration of the cerebrospinal fluid by malignant B-cells, confirmed by lumbar puncture.
- •Cancer chemotherapy within 4 weeks prior to start of AFM11 treatment, or at least 4 times the respective half-lives, whichever is longer.
- •Radiotherapy within 4 weeks prior to start of AFM11 treatment.
- •Therapy with antibody, or antibody constructs within 4 weeks prior to start of AFM11 treatment, or at least 4 times the respective half-lives, whichever is longer.
- •Prior treatment with alemtuzumab (Campath®) within 12 weeks prior to start of AFM11 treatment.
- •Treatment with any investigational agent within 4 weeks prior to start of AFM11 treatment, or at least 4 times the respective half-life, whichever is longer.
- •Contraindication for any of the concomitant medications.
- •Abnormal renal or hepatic function as follows: aspartate aminotransferase (AST or serum glutamic oxaloacetic transaminase [SGOT]) and/or alanine aminotransferase (ALT or serum glutamic pyruvic transaminase [SGPT]) ≥ 2.5 × upper limit of normal (ULN); total bilirubin ≥ 1.5 × ULN; serum creatinine ≥ 2 × ULN; creatinine clearance < 50 mL/minute.
- •History of malignancy other than B-cell lymphoma within 5 years prior to study entry, with the exception of basal cell carcinoma of the skin or carcinoma in situ of the cervix.
- •Active autoimmune disease requiring systemic immunosuppressive treatment.
- •Uncontrolled infections; known bacteremia.
- •Any concurrent disease or medical condition that is deemed to interfere with the conduct of the study as judged by the Investigator.
- •Regular dose of corticosteroids during the 4 weeks prior to start of AFM11 treatment or anticipated need of continuous corticosteroids exceeding prednisone 20 mg/day or equivalent, or any other immunosuppressive therapy within 4 weeks prior to start of AFM11 treatment.
- •Known infection with human immunodeficiency virus (HIV) or chronic infection with hepatitis B or hepatitis C virus.
- •Pregnant or nursing women or women of childbearing potential not willing to use an effective form of contraception during participation in the study and at least 12 weeks thereafter. Male patients not willing to ensure that during the study and at least 12 weeks thereafter no fathering takes place. Effective methods of contraception include intrauterine device 8(IUD), combined (estrogen- and progesterone-containing) hormonal contraception (oral, vaginal ring or transdermal patch) with an ethinylestradiol dose of at least 30 µg, plus use of male condoms (preferably with spermicides), female condoms, female diaphragm, or cervical cap.
- •Prior treatment with blinatumomab or any other CD19 targeting T-cell engager, including CD19 CAR-T cells.
- •Clinically relevant coronary artery disease (New York Heart Association [NYHA] functional angina classification III/IV), congestive heart failure (NYHA III/IV), or high risk of, or known, uncontrolled arrhythmia.
研究组 & 干预措施
AFM11
Experimental
IV (intravenous) infusion, dose escalation
干预措施: AFM11 (Drug)
结局指标
主要结局
Number of participants with serious and non-serious adverse events as a measure of safety and tolerability of AFM11.
时间窗: From administration of the first dose of study drug and through 30 days after the last dose, up to 8 weeks.
Measure occurence of adverse events until the Final Study Visit and monitor laboratory safety parameters at least once weekly. Assess immunogenicity of AFM11 at end of treatment cycle.
次要结局
- Maximum Tolerated Dose (MTD) of AFM11.(up to 8 weeks)
- Pharmacokinetic profile of AFM11 and immunological markers of AFM11 activity.(Prior to initial dose on Day 1 and at multiple time points during the 4 weeks of treatment until up to 30 days after the last dose.)
- Tumor Response.(Baseline and at week 6.)
研究者
研究点 (7)
Loading locations...
相似试验
已完成
1 期
Study of the Combination of AFM13 and Pembrolizumab in Patients With Relapsed or Refractory Classical Hodgkin LymphomaHodgkin LymphomaNCT02665650Affimed GmbH30
已完成
2 期
Study of Pharmacokinetics, Efficacy and Safety of a Recombinant and Protein-Free Factor VIII (rAHF-PFM) in Hemophilia A Patients - A Continuation of Clinical Study 069901Hemophilia ANCT00157053Baxalta now part of Shire82
已完成
3 期
AM-111 in the Treatment of Acute Inner Ear Hearing LossHearing LossNCT02561091Auris Medical AG256
已完成
1 期
A Phase I Study of Intravenous Aflibercept in Combination With Docetaxel in Japanese Cancer PatientsNeoplasmsNCT00545246Sanofi12
已完成
1 期
Study of Intravenous Aflibercept in Combination With FOLFIRI in Japanese Patients With Metastatic Colorectal CancerNeoplasm MetastasisColorectal NeoplasmsNCT00921661Sanofi16